Advertisement
GSK vs MRK
Which Stock Would AI Choose? GSK plc (GSK) vs. Merck & Co., Inc. (MRK) Stock Comparison
Key Takeaways
- GSK is a diversified UK-based biopharmaceutical company whose growth is led by Specialty Medicines, HIV, oncology, and vaccines, while MRK is a larger US-based pharma anchored by oncology giant Keytruda.
- Over the past year, MRK has delivered materially stronger share-price appreciation, while GSK has posted steadier, more value-oriented gains with a higher dividend yield.
- GSK recently raised its full-year sales and profit guidance and is undergoing a CEO transition, supporting renewed investor confidence.
- MRK is navigating the 2028 patent cliff (loss of exclusivity) for Keytruda and softer Gardasil demand in China, even as newer drugs and acquisitions strengthen its pipeline.
- The two companies differ in market positioning: MRK offers scale and oncology leadership, while GSK offers diversification across vaccines, HIV, and respiratory/immunology.
- For more detail on these tickers' major news and today's price moves, explore GSK Major News and GSK Today's Price Move, as well as MRK Major News and MRK Today's Price Move.
- To see how automated strategies are positioning across the market, explore the curated Trending AI Robots.
Introduction
Pharmaceutical stocks attract investors seeking defensive cash flows, pipeline-driven growth, and durable dividend income, yet no two names in the sector are interchangeable. This stock comparison evaluates GSK (GSK plc, the UK-headquartered healthcare group) against MRK (Merck & Co., Inc., a US-based pharmaceutical leader). Both companies operate in human health, but they differ sharply in scale, growth drivers, and recent price behavior. This relative performance review is relevant for investors weighing a diversified, dividend-rich UK pharma against a larger US oncology franchise, and for traders monitoring momentum shifts and catalysts across the sector.
GSK Overview and Recent Performance
GSK operates across three segments: Specialty Medicines (including HIV, respiratory/immunology, and oncology), Vaccines, and General Medicines. In recent weeks, the company has reinforced investor confidence by raising its full-year sales and profit outlook, supported by double-digit growth in Specialty Medicines and resilient HIV and immunology demand. Management has also signaled disciplined investment, including an expanded focus on oncology following its acquisition of Nuvalent and a commitment to substantial US research and development (R&D) and manufacturing spending. A notable transition is underway: long-time CEO Emma Walmsley has handed leadership to Luke Miels, with the company reaffirming an ambition to exceed £40 billion in annual sales by 2031. Despite steady earnings per share (EPS) growth, recent market activity has reflected some caution around vaccine pricing pressure and patent expiries, contributing to a more measured, value-oriented share performance relative to its US peer.
MRK Overview and Recent Performance
MRK is one of the world's largest pharmaceutical companies, with a portfolio spanning oncology, vaccines, cardiometabolic and respiratory therapies, and a sizable animal health business. Its franchise is led by Keytruda, a top-selling immunotherapy that continues to generate substantial revenue across multiple cancer indications. Recent market activity has been shaped by strong share-price momentum over the past year, driven by pipeline progress, an expanding roster of newer products such as Winrevair (for pulmonary arterial hypertension, or PAH), and a series of acquisitions including Cidara Therapeutics and Verona Pharma. At the same time, sentiment is tempered by the approaching 2028 loss of exclusivity for Keytruda and by weaker Gardasil vaccine sales tied to lower demand in China. The company's elevated price-to-earnings (P/E) ratio also reflects acquisition-related and non-cash items, making earnings-based valuation appear stretched relative to historical norms.
Trending AI Robots
Tickeron maintains a large library of AI Trading Bots, with hundreds of automated strategies that collectively trade thousands of different tickers across varied timeframes and market conditions. Because each bot carries its own trading style, strategy, performance record, and set of securities, not every strategy fits every market environment. The Trending AI Robots page curates only those strategies currently best suited to prevailing conditions, helping traders filter through the noise and identify bots with momentum, stability, and favorable recent statistics. Whether you are monitoring GSK, MRK, or the broader market, reviewing this curated selection can provide useful, data-driven context for your own analysis.
Head-to-Head Comparison
The clearest contrast between these two stocks is scale and specialization. MRK carries a market capitalization several times larger than GSK and derives a concentrated share of its revenue from a single oncology franchise, which creates both a powerful growth engine and a key concentration risk ahead of the Keytruda patent cliff. GSK, by contrast, offers broader therapeutic and geographic diversification across vaccines, HIV, and respiratory/immunology, which can smooth results but may limit upside during oncology-driven rallies.
On momentum, MRK has recently outpaced GSK in relative performance, while GSK has offered a more defensive profile with a higher dividend yield and lower valuation multiple. Risk factors also differ: MRK faces China-related vaccine headwinds and patent-expiry concerns, whereas GSK contends with pricing pressure, litigation history, and the execution risks of a leadership transition. These trade-offs make the two names complementary rather than interchangeable within a healthcare allocation.
Tickeron AI Verdict
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI would likely lean toward MRK in the current environment. The stock has demonstrated stronger and more sustained upward momentum over recent quarters, supported by visible pipeline catalysts and an active acquisition strategy. GSK presents a compelling, lower-volatility alternative with attractive income and improving guidance, but its trend profile has been more gradual and its catalysts more dependent on successful execution through a management change. This assessment is probabilistic rather than definitive, reflecting momentum and positioning factors that can shift as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and MRK is a Hold.
GSK in -1.60% downward trend, falling for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GSK declined for three days, in 159 of 287 cases, the price declined further within the following month. The odds of a continued downward trend are 55%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In 37 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GSK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GSK's RSI Indicator exited the oversold zone, 15 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on November 04, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 30 of 46 cases over the following month. The odds of a continued upward trend are 65%.
GSK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.715) is normal, around the industry mean (-1.360). P/E Ratio (20.988) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.036) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
MRK in -2.41% downward trend, declining for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MRK declined for three days, in 140 of 273 cases, the price declined further within the following month. The odds of a continued downward trend are 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 44%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MRK as a result. In 55 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 30, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 27 of 50 cases over the following month. The odds of a continued upward trend are 54%.
MRK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 177 of 265 cases where MRK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.633) is normal, around the industry mean (-1.360). MRK's P/E Ratio (116.452) is considerably higher than the industry average of (21.695). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
GSK | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 35 | 29 | |
SMR RATING 1..100 | 34 | 79 | |
PRICE GROWTH RATING 1..100 | 47 | 8 | |
P/E GROWTH RATING 1..100 | 8 | 1 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (81) in the Pharmaceuticals Major industry is in the same range as MRK (88). This means that GSK’s stock grew similarly to MRK’s over the last 12 months.
MRK's Profit vs Risk Rating (29) in the Pharmaceuticals Major industry is in the same range as GSK (35). This means that MRK’s stock grew similarly to GSK’s over the last 12 months.
GSK's SMR Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (79). This means that GSK’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (8) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (47). This means that MRK’s stock grew somewhat faster than GSK’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as GSK (8). This means that MRK’s stock grew similarly to GSK’s over the last 12 months.
| GSK | MRK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 65% | N/A |
| Stochastic ODDS (%) | 1 day ago 33% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 48% | 1 day ago 65% |
| MACD ODDS (%) | 1 day ago 65% | 1 day ago 54% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 49% |
| TrendMonth ODDS (%) | 1 day ago 59% | 1 day ago 57% |
| Advances ODDS (%) | 23 days ago 63% | 9 days ago 57% |
| Declines ODDS (%) | 1 day ago 55% | 1 day ago 51% |
| BollingerBands ODDS (%) | 1 day ago 42% | 4 days ago 57% |
| Aroon ODDS (%) | 1 day ago 46% | 1 day ago 67% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green while MRK’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 5 TA indicator(s) are bullish while MRK’s TA Score has 7 bullish TA indicator(s).
- GSK’s TA Score: 5 bullish, 5 bearish.
- MRK’s TA Score: 7 bullish, 2 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +1.66% price change this week, while MRK (@Pharmaceuticals: Major) price change was -1.87% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
Reported Earning Dates
GSK is expected to report earnings on Feb 03, 2027.
MRK is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.